The FLOW trial showed semaglutide reduced kidney disease progression by 24% in people with type 2 diabetes, with the investigators stating the kidney benefit was unrelated to weight changes
Thymosin Alpha-1 the most underrated peptide in the space Dihexa, Epitalon, Glutathione, and the future of peptide delivery formats Hair loss on GLPs what's actually happening Hormones as the foundation: why estrogen is a hero for women AND men The metabolic aging events at age 44 and 60 how to get ahead of them Sarah's Amino Academy course what's in it and who it's for Want to go deeper on everything Sarah covered in this episode
While extended services such as pharmacist-led weight-management programs or counseling can bridge the gap, they are offered at an additional payment, which can deter patients from utilizing these services (Alharthi 2024)
But the glucagon receptor activation introduces entirely new metabolic effects that researchers find particularly compelling for specific patient populations
The New Frontier: Ethics, Access, and The Future of Fair Play Retatrutide raises profound questions for the fitness community: The Prescription Barrier: Is this primarily a medicine for obesity treatment, or the next evolution of performance enhancement
The goal is to lose fat while maintaining strength, mobility, and metabolic function